ESC Launches New Concept for Driving Innovation in Cardiovascular Research with Exclusive Support from Boehringer Ingelheim
August 29 2015 - 9:49AM
Business Wire
- Four grants will be awarded to
independent research projects, focused on improving patient
outcomes in thromboembolic diseases
- Grant programme reflects commitment of
Boehringer Ingelheim and the ESC to advancing cardiovascular
medicine
- Applications are open from today; ESC
Scientific Committee to select grant winners after live
presentations by finalists in December 2015
For UK medical and consumer media only
The European Society of Cardiology (ESC) today announced the
launch of the competitive medical research programme “ESC Grants
for Medical Research Innovation”, exclusively supported by an
independent grant from Boehringer Ingelheim. The programme aims to
support research into areas of medical need in cardiovascular
medicine. Four grants of up to €400,000 each will be awarded to
researchers or clinicians following live presentations by selected
finalists to a panel of high profile experts appointed by the
ESC.
“We are really excited to support the ESC in launching this
unique peer challenge grant concept. We believe this will stimulate
exciting new research with the ultimate ambition of improving the
lives of patients,” said Professor J�rg Kreuzer, Vice President
Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim.
“We are encouraging clinicians and researchers to submit their
proposals to the ESC.”
“This grant project is a reflection of the ESC’s commitment to
encouraging new and innovative research aimed at improving patient
outcomes in thromboembolic disease – a leading cause of mortality
worldwide,” said Professor Francesco Cosentino, the chair of the
programme’s scientific committee. “It is estimated that one in four
people die as a result of thromboembolic disease, which causes
abnormal blood clotting, and more research into this disorder is
urgently needed. We are excited about this initiative because it is
a great opportunity to perform important studies aiming to a better
understanding of novel therapeutic strategies in this setting. We
are now ready to receive applications from around the world for
these prestigious grants - until the November 1st deadline - and
look forward to announcing the four winners at European Heart House
on December 1st following live presentations by all finalists.
The ESC Grants for Medical Research Innovation website, which
includes details about the research categories, applicant
eligibility and information about how to submit an entry for the
peer challenge, is accessible from today via:
www.escardio.org/innovationgrants.
The application deadline is 1 November 2015 and projects awarded
funding will be announced in December 2015.
ENDS
NOTES TO THE EDITORS
About ESC Grants for Medical Research Innovation
The ESC Grants for Medical Research Innovation will focus on
improving patient outcomes in thromboembolic diseases.
The four awarded grants of up to €400,000 each will be made
possible by an independent grant from Boehringer Ingelheim.
Applications for projects are encouraged from medical professionals
and research scientists from around the world.
The evaluation and selection process of the researchers will be
conducted by a dedicated Scientific Committee independently
appointed by the ESC. The Committee will evaluate all grant
proposals. Studies selected are required to have a publishable
outcome or data within 18 months from the grant being awarded.
Distinct from other programmes, a short list of up to 8 applicants
will be invited to present and defend their proposals live to the
Scientific Committee at the European Heart House in Nice. The
Committee will then decide on the same day the winners, and will
continue to oversee the implementation of the successful research
programmes.
About thromboembolic diseases
Thromboembolic diseases, or diseases that can cause abnormal
blood clotting. This includes atrial fibrillation, stroke, deep
vein thrombosis, pulmonary embolism, percutaneous coronary
intervention and coronary artery disease and/or peripheral artery
disease. One in four people die from causes related to thrombosis;
it is a leading cause of mortality worldwide – ongoing research
into the area is vital to enhance the treatment and care for
patients at risk.
About the European Society of Cardiology
www.escardio.org
The European Society of Cardiology (ESC) represents more than 90
000 cardiology professionals across Europe and worldwide. Its
mission is to reduce the burden of cardiovascular disease in
Europe.
Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading
pharmaceutical companies. Headquartered in Ingelheim, Germany,
Boehringer Ingelheim operates globally with 146 affiliates and a
total of more than 47,700 employees. The focus of the family-owned
company, founded in 1885, is researching, developing, manufacturing
and marketing new medications of high therapeutic value for human
and veterinary medicine.
Social responsibility is an important element of the corporate
culture at Boehringer Ingelheim. This includes worldwide
involvement in social projects, such as the initiative “Making more
Health” and caring for the employees. Respect, equal opportunities
and reconciling career and family form the foundation of the mutual
cooperation. In everything it does, the company focuses on
environmental protection and sustainability.
In 2014, Boehringer Ingelheim achieved net sales of about 13.3
billion euros. R&D expenditure corresponds to 19.9 per cent of
its net sales.
For more information please
visit www.boehringer-ingelheim.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150829005017/en/
Boehringer Ingelheim LimitedNick JohnsonCommunications
ManagerTel: +44 (0)1344
742534nick.johnson@boehringer-ingelheim.com